Abvance Therapeutics

About Abvance Therapeutics

Abvance Therapeutics is dedicated to revolutionizing diabetes care by developing innovative therapies that balance blood sugar control while managing the fear of hypoglycemia. Their mission is deeply personal, aiming to transform the lives of people with diabetes by reducing the constant anxiety associated with blood sugar excursions and giving patients freedom, confidence, and peace of mind.

Products & Services

ABV101:A pioneering therapy combining insulin and glucagon to prevent dangerous blood sugar crashes, enabling confident glycemic control, integrating with current treatment protocols, and aiming to transform the patient experience from vigilance to confidence.

Specialties

Diabetes care Insulin therapy innovation Hypoglycemia management Glucagon-based therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 3900000 MR: - FA: 3.9 million FAN: 3900000	D: 2024-09-10 FD: 2024-09-10	1 investors

Debt Latest

2024-09-10

$3.9M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Maggs

Chief Executive Officer and Co-founder

S

Soumitra Ghosh

Co-founder and Scientific Advisor

E

Edward Raskin

General Counsel and Corporate Secretary

G

Gibb Clarke

Chief Financial Officer

V

Veena Rao

Chief Operating Officer

M

Michael Nguyen

Vice President of Development

View 12 more team members with Pro

Unlock Full Team Directory

Recent News